Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy

ConclusionElectronic mobile wearable device monitoring in symptomatic NDMM patients may be a useful tool to assess a patient's overall wellness and health as they are receiving chemotherapy. For three patients, we were able to capture a dramatic increase in activity after initiation of treatment. Overall activity in the elderly NDMM patients is decreased compared to younger patients. Mobile wearable monitoring may be an even more useful strategy for tracking elderly and unfit patients that are more prone to side effects, where the balance of response versus quality of life is paramount.Figure.DisclosuresMailankody: Physician Education Resource: Honoraria; Janssen: Research Funding; Takeda: Research Funding; Juno: Research Funding. Hassoun: Oncopeptides AB: Research Funding. Lesokhin: Squibb: Consultancy, Honoraria; Serametrix, inc.: Patents & Royalties: Royalties; Janssen: Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; Takeda: Consultancy, Honoraria. Smith: Celgene: Consultancy, Patents & Royalties: CAR T cell therapies for MM, Research Funding. Shah: Amgen: Research Funding; Janssen: Research Funding. Landgren: Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Research Funding; Pfizer: Consultancy; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, ...

Source: Blood - November 21, 2018 Category: Hematology Authors: Tavitian, E., Mastey, D., Salcedo, M., Zarski, A., Chansakul, A., Diab, V., Mailankody, S., Hassoun, H., Lesokhin, A. M., Lendvai, N., Smith, E. L., Hultcrantz, M., Sams, A., Davis, M., Davis, E., Puklin, S., Steinberger, A., Shah, G. L., Landgren, O., At Tags: 902. Health Services Research-Malignant Diseases: Poster III Source Type: research